Figure 4.

Oncomine analysis of BRF2 expression in gastric, kidney, melanoma and lung cancers. As seen in Figure 3, BRF2 is significantly overexpressed in gastric, kidney and melanoma cancer datasets within the Oncomine datasets. We further queried Oncomine for each of these specific cancers to compare the fold change of BRF2 expression in the cancerous tissue compared to the controls for each specific cancer. All p-values represent a student's t-test. Figure 4A shows that BRF2 is overexpressed in cutaneous melanomas compared to normal skin in the Talantov Melanoma dataset [58]. BRF2 overexpression is significant with a p-value of 1.15E-15 and a total of 70 patient samples used for this analysis. Figure 4B shows that BRF2 is overexpressed in clear cell renal carcinoma compared to normal kidney in the Gumz Renal dataset [59]. BRF2 overexpression is significant with a p-value of 7.64E-5 and a total of 20 patient samples were used for this analysis. Figure 4C shows that BRF2 is overexpressed in diffuse gastric adenocarcinoma versus normal gastric mucosa in the DErrico Gastric dataset [60]. BRF2 overexpression is significant with a p-value of 5.35E-5 and a total of 69 patient samples were used for this analysis. Lastly, Figure 4D shows that BRF2 is overexpressed in advance N1+ stage lung adenocarcinoma compared to N0 stage in the Garber Lung Adenocarcinoma dataset [61]. BRF2 overexpression is significant with a p-value of 0.023 and a total of 73 patient samples were analyzed. (Oncomine database).